Stock Scorecard
Stock Summary for Royalty Pharma plc - Class A (RPRX) - $27.89 as of 4/18/2024 10:31:12 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RPRX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RPRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RPRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for RPRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for RPRX
Financial Details for RPRX
Company Overview |
|
|---|---|
| Ticker | RPRX |
| Company Name | Royalty Pharma plc - Class A |
| Country | USA |
| Description | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/9/2024 |
Stock Price History |
|
| Last Day Price | 27.89 |
| Last Day Price Updated | 4/18/2024 10:31:12 PM EST |
| Last Day Volume | 2,091,891 |
| Average Daily Volume | 2,373,331 |
| 52-Week High | 35.49 |
| 52-Week Low | 25.54 |
| Last Price to 52 Week Low | 9.20% |
Valuation Measures |
|
| Trailing PE | 10.85 |
| Industry PE | 100.90 |
| Sector PE | 61.34 |
| 5-Year Average PE | 8.60 |
| Free Cash Flow Ratio | 25.13 |
| Industry Free Cash Flow Ratio | 12.64 |
| Sector Free Cash Flow Ratio | 30.17 |
| Current Ratio Most Recent Quarter | 7.90 |
| Total Cash Per Share | 1.11 |
| Book Value Per Share Most Recent Quarter | 14.61 |
| Price to Book Ratio | 1.93 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 7.16 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
| Total Shares Outstanding | 446,692,000 |
| Market Capitalization | 12,458,239,880 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 2/15/2024 |
| Last Dividend Amount | 0.21 |
| Current Dividend Amount | 0.21 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 1.02 |
| Trailing Annual Dividend Yield | 3.69% |
| Forward Annual Dividend Rate | 1.41 |
| Forward Annual Dividend Yield | 5.12% |
| 5-Year Dividend Payments Count | 16 |
| 3-Year Average Dividend Yield | 2.16% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 5.26% |
| 3-Year Dividend Growth Rate Percentage | 8.47% |
| 5-Year Dividend Growth Rate Percentage | 38.67% |
| All-Time Dividend Growth Rate Percentage | 38.67% |
| Dividend Payout Ratio | 40.32% |
Income Statement |
|
| Quarterly Earnings Growth YOY | -50.70% |
| Annual Earnings Growth | 2,549.50% |
| Reported EPS 12 Trailing Months | 2.53 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | 4.38 |
| Net Income Twelve Trailing Months | 1,134,834,000 |
| Net Income Past Year | 1,134,834,000 |
| Net Income Prior Year | 42,832,000 |
| Quarterly Revenue Growth YOY | 5.40% |
| 5-Year Revenue Growth | 3.52% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 495,310,000 |
| Total Cash Past Year | 495,310,000 |
| Total Cash Prior Year | 1,736,472,000 |
| Net Cash Position Most Recent Quarter | -5,639,975,000 |
| Net Cash Position Past Year | -5,639,975,000 |
| Long Term Debt Past Year | 6,135,285,000 |
| Long Term Debt Prior Year | 7,116,322,000 |
| Total Debt Most Recent Quarter | 6,135,285,000 |
| Equity to Debt Ratio Past Year | 0.62 |
| Equity to Debt Ratio Most Recent Quarter | 0.62 |
| Total Stockholder Equity Past Year | 10,084,289,000 |
| Total Stockholder Equity Prior Year | 9,525,373,000 |
| Total Stockholder Equity Most Recent Quarter | 10,084,289,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.53 |
| MACD Signal | -0.30 |
| 20-Day Bollinger Lower Band | 26.61 |
| 20-Day Bollinger Middle Band | 28.91 |
| 20-Day Bollinger Upper Band | 31.22 |
| Beta | 0.45 |
| RSI | 28.96 |
| 50-Day SMA | 29.17 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 4/18/2024 10:39:23 AM EST |